Breaking News Instant updates and real-time market news.

MYL

Mylan

$38.75

-0.46 (-1.17%)

, TEVA

Teva

$31.83

-0.07 (-0.22%)

07:59
07/18/17
07/18
07:59
07/18/17
07:59

Novartis report has cautious read-through for Mylan, Teva, says Wells Fargo

Wells Fargo analyst David Maris noted that Novartis' (NVS) Sandoz unit is one of the world's largest generic drug makers and he believes the proper read-through from its report is that the U.S. generic market remains challenging and that investors should remain cautious on the generics space. Maris, who said he would not be surprised to see Mylan (MYL) or Teva (TEVA) weaker following Novartis' report, keeps Market Perform ratings on those two names.

MYL

Mylan

$38.75

-0.46 (-1.17%)

TEVA

Teva

$31.83

-0.07 (-0.22%)

NVS

Novartis

$83.27

0.11 (0.13%)

  • 18

    Jul

  • 19

    Jul

  • 03

    Aug

  • 30

    Aug

  • 03

    Sep

  • 09

    Oct

MYL Mylan
$38.75

-0.46 (-1.17%)

06/21/17
WELS
06/21/17
NO CHANGE
WELS
Market Perform
Wells wouldn't be surprised to see greater scrutiny on Mylan coal tax credits
After a new report from Reuters questioned the way in which Mylan uses its ownership of coal processing plants to keep its taxes low, Wells Fargo analyst David Maris said this topic has interested him for some time but his questions to management on the issue were not answered. Maris, who said he would not be surprised to see greater public scrutiny on this issue after the report, keeps a Market Perform rating on Mylan shares.
06/16/17
CANT
06/16/17
INITIATION
Target $41
CANT
Neutral
Mylan initiated with a Neutral at Cantor
Cantor Fitzgerald analyst Louise Chen started Mylan with a Neutral rating and $41 price target.
06/12/17
SBSH
06/12/17
NO CHANGE
Target $38
SBSH
Buy
Citi says CRL for Coherus not worst case scenario
Citi analyst Mohit Bansal says Coherus Biosciences' (CHRS) complete response letter for its biosimilar version of Neulasta, while "clearly a negative outcome," is not the worst case scenario since the FDA did not ask for another study. The analyst sees a one year delay, which impacts his discounted free cash flow model by $5 per share. Coherus in premarket trading is down 30%, or $6.25, to $14.40. A one year delay would mean Coherus' CHS-1701 could still be on markets at the same time as competition from Mylan (MYL) and ahead of Sandoz's approval in 2019, Bansal tells investors in a research note. The analyst has a Buy rating on Coherus with a $38 price target.
05/31/17
WELS
05/31/17
NO CHANGE
WELS
Market Perform
Pension fund campaign a short-term negative for Mylan, says Wells Fargo
Wells Fargo analyst David Maris believes the campaign by four major pension funds to oppose the re-election of six directors is short-term negative for Mylan but has the potential to be a longer term positive. The campaign may pose a distraction to management, but if successful, it could address some governance concerns regarding compensation and performance at the company, Maris tells investors in a research note. The analyst has a Market Perform rating on Mylan shares.
TEVA Teva
$31.83

-0.07 (-0.22%)

07/13/17
SBSH
07/13/17
NO CHANGE
Target $42
SBSH
Buy
Teva landing Soriot would be 'material positive,' says Citi
Citi analyst Liav Abraham believes Calcalist's report of Teva (TEVA) hiring away AstraZeneca's (AZN) CEO Pascal Soriot has credibility given the "relatively accurate track record" of the Israeli press in the "leaking" of information pertaining to Teva. The news, if confirmed, would be a "material positive" for Teva over the near to medium term, Abraham tells investors in a research note. She believes Soriot would "lend significant credibility" to Teva's turnaround thesis. On the other side, Soriot leaving would increase concerns over the pending outcome of AstraZeneca's MYSTIC trial, which constitutes the dominant near-term driver for the shares, Abraham argues. She has a Buy rating on Teva with a $42 price target. The stock in premarket trading is up 2% to $32.80. AstraZeneca is down 14c to $32.78.
07/13/17
LEER
07/13/17
NO CHANGE
LEER
Outperform
AstraZeneca CEO departure now would have 'terrible' optics, says Leerink
Leerink analyst Seamus Fernandez said the media report that AstraZeneca (AZN) CEO Pascal Soriot may be leaving the company to take over at Teva (TEVA) comes as a "major surprise," adding that while the company would not comment to him on the rumor it also did not outright deny the report. While the news does not appear to be related to the outcome of the MYSTIC trial in non-small cell lung cancer, the optics around such a departure at this would be "terrible" and his loss would be a "clear negative" for AstraZeneca, according to Fernandez, who has an Outperform rating on Astra shares.
06/27/17
WELS
06/27/17
NO CHANGE
WELS
Market Perform
Teva TV-45070 trial miss a 'modest disappointment,' says Wells Fargo
Wells Fargo analyst David Maris said TV-45070 has not been a focus for Teva (TEVA) investors, but he still views the news that the company and partner Xenon Pharmaceuticals' (XENE) Phase 2 trial in post-herpetic neuralgia missed its primary endpoint as a "modest disappointment" given the need for Teva's pipeline to offset the tough generic market and the eventual competition for Copaxone. Maris keeps a Market Perform rating on Teva.
07/05/17
OPCO
07/05/17
NO CHANGE
Target $70
OPCO
Outperform
Neurocrine Ingrezza 'holds steady' after competitor data, says Oppenheimer
Oppenheimer analyst Jay Olson notes that Teva's (TEVA) Austedo could become a competitor to Neurocrine's (NBIX) Ingrezza with a PDUFA date for the tardive dyskinesia indication on August 30, 2017. However, the analyst sees Ingrezza as well positioned and reiterates an Outperform rating and $70 price target on Neurocrine's shares. A key factor to follow beyond the short trials will be real-life performance considering the number needed to treat to observe a 50% AIMS improvement was 5 for Austedo and 4 for Ingrezza, he contends.
NVS Novartis
$83.27

0.11 (0.13%)

07/14/17
LEER
07/14/17
NO CHANGE
Target $36
LEER
Outperform
Leerink sees significant optionality for AstraZeneca beyond MYSTIC trial
Leerink analyst Seamus Fernandez said he sees significant optionality for AstraZeneca (AZN) beyond the "mega-catalyst" of the MYSTIC trial in non-small cell lung cancer, as he believes several 2017 and 2018 readouts from underappreciated pipeline assets could lead to upside for the shares. If MYSTIC fails, Astra's "massive" SG&A spend gives it flexibility to mute the bottom-line impact. If it is successful, he believes potential acquirers such as Pfizer (PFE) or Novartis (NVS) could see "an attractive target to plunder," Fernandez tells investors. He keeps an Outperform rating and $36 price target on AstraZeneca ADRs.
07/13/17
SBSH
07/13/17
NO CHANGE
SBSH
Novartis vote bodes well for Kite and Juno, says at Citi
Citi analyst Robyn Karnauskas believes the FDA's unanimous vote in favor of Novartis' (NVS) CAR-T bodes well for Kite Pharma (KITE) and Juno Therapeutics (JUNO). Yesterday's panel meeting provides a preview of what Kite can expect ahead of its November 29 FDA action date, Karnauskas tells investors in a research note. She believes the expert commentary from the panel has "overarching implications" for Kite and Juno, both of which are developing CAR-T therapies for multiple indications.
07/12/17
RHCO
07/12/17
NO CHANGE
Target $108
RHCO
Buy
bluebird bio recent weakness unwarranted, says SunTrust
SunTrust analyst Edward Nash views the weakness in bluebird bio (BLUE) shares since the FDA briefing document on Novartis' (NVSR) CAR T product candidate as unwarranted. The tone of the briefing document is neutral and emphasizes short-term toxicities observed in Novartis' studies and long-term safety concerns so that the Advisory Committee will be able to conduct a thorough discussion to determine the risk/benefit ratio, Nash tells investors in a research note. Further, he believes the data from Novartis and bluebird are not an apples-to-apples comparison and reminds investors of the "differentiated safety profile" that bluebird's bb2121 has demonstrated to date. He recommends buying bluebird on the recent selloff and reiterates a Buy rating on the name with a $108 price target.
07/10/17
JEFF
07/10/17
NO CHANGE
Target $121
JEFF
Buy
Jefferies ups Kite target to $121 on 'relatively benign' FDA docs
Jefferies analyst Biren Amin raised his price target for Kite Pharma (KITE) shares to $121 from $101 after the FDA posted briefing documents ahead of the July 12 committee meeting disusing Novartis' (NVS) CAR-T therapy CTL019. The documents for the first CAR-T therapy seem "relatively benign," Amin tells investors in a research note. The FDA's view of CAR-T therapies looks in-line with expectations, but the agency may require long-term follow-up of patients to assess for risk of secondary malignancies, Amin writes. He keeps a Buy rating on Kite Pharma. The stock in late morning trading is down 3% to $102.55.

TODAY'S FREE FLY STORIES

AKBA

Akebia

, MACK

Merrimack

$1.30

0.02 (1.56%)

08:51
07/21/17
07/21
08:51
07/21/17
08:51
Periodicals
Former Akebia employee faces losing bail in insider trading case, Reuters says »

Schultz Chan, former…

AKBA

Akebia

MACK

Merrimack

$1.30

0.02 (1.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMC

AMC Entertainment

$20.60

0.75 (3.78%)

08:51
07/21/17
07/21
08:51
07/21/17
08:51
Initiation
AMC Entertainment initiated  »

AMC Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 05

    Sep

SIX

Six Flags

$56.28

-1.01 (-1.76%)

08:50
07/21/17
07/21
08:50
07/21/17
08:50
Initiation
Six Flags initiated  »

Six Flags initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

LYV

Live Nation

$36.38

-0.01 (-0.03%)

08:50
07/21/17
07/21
08:50
07/21/17
08:50
Initiation
Live Nation initiated  »

Live Nation initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNP

Union Pacific

$106.14

-1.7 (-1.58%)

08:50
07/21/17
07/21
08:50
07/21/17
08:50
Recommendations
Union Pacific analyst commentary  »

Market ignorning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

MTN

Vail Resorts

$206.11

0.09 (0.04%)

08:50
07/21/17
07/21
08:50
07/21/17
08:50
Initiation
Vail Resorts initiated  »

Vail Resorts initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$26.69

-0.25 (-0.93%)

08:49
07/21/17
07/21
08:49
07/21/17
08:49
Hot Stocks
Breaking Hot Stocks news story on General Electric »

General Electric down 3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

  • 02

    Oct

GPC

Genuine Parts

$81.69

-1.27 (-1.53%)

08:47
07/21/17
07/21
08:47
07/21/17
08:47
Upgrade
Genuine Parts rating change  »

Genuine Parts upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLB

Schlumberger

$67.02

-0.42 (-0.62%)

08:46
07/21/17
07/21
08:46
07/21/17
08:46
Hot Stocks
Schlumberger says expects to double SPM revenue over next two years »

Says has invested $4.3B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

GE

General Electric

$26.69

-0.25 (-0.93%)

08:45
07/21/17
07/21
08:45
07/21/17
08:45
Hot Stocks
General Electric CFO says 'trending to bottom end' of $1.60-$1.70 FY17 EPS view »

GE CFO Jeff Bornstein…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

  • 02

    Oct

ITW

Illinois Tool Works

$147.12

-0.56 (-0.38%)

08:45
07/21/17
07/21
08:45
07/21/17
08:45
Technical Analysis
Technical Earnings Preview: Illinois Tool Works in uptrend ahead of news »

The shares have been in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

XRT

S&P Retail Index SPDR

$40.59

0.09 (0.22%)

, PAA

Plains All American

$26.47

-0.16 (-0.60%)

08:45
07/21/17
07/21
08:45
07/21/17
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

XRT

S&P Retail Index SPDR

$40.59

0.09 (0.22%)

PAA

Plains All American

$26.47

-0.16 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 08

    Nov

SLB

Schlumberger

$67.02

-0.42 (-0.62%)

08:41
07/21/17
07/21
08:41
07/21/17
08:41
Hot Stocks
Schlumberger says all U.S. product lines profitable in Q2 »

Says expect high demand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

HIMX

Himax

$8.86

0.34 (3.99%)

08:41
07/21/17
07/21
08:41
07/21/17
08:41
Downgrade
Himax rating change  »

Himax downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 05

    Sep

SLM

Sallie Mae

$10.98

-0.83 (-7.03%)

08:41
07/21/17
07/21
08:41
07/21/17
08:41
Recommendations
Sallie Mae analyst commentary  »

Sallie Mae shares should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLB

Schlumberger

$67.02

-0.42 (-0.62%)

08:38
07/21/17
07/21
08:38
07/21/17
08:38
Hot Stocks
Schlumberger says 'confident' in delivering free cash flow target for 2017 »

Comments from Q2 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

EXPI

eXp World Holdings

$2.95

-0.04 (-1.34%)

08:36
07/21/17
07/21
08:36
07/21/17
08:36
Initiation
eXp World Holdings initiated  »

eXp World Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CXDC

China XD Plastics

$4.70

-0.025 (-0.53%)

08:35
07/21/17
07/21
08:35
07/21/17
08:35
Hot Stocks
China XD Plastics signs investment agreements for $614M in Harbin, China »

China XD Plastics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAAP

Advanced Accelerator

$41.13

0.56 (1.38%)

08:35
07/21/17
07/21
08:35
07/21/17
08:35
Hot Stocks
Advanced Accelerator: CHMP opinion recommending approval of 177Lu oxodotreotide »

Advanced Accelerator…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNB

F.N.B.

$13.59

-0.56 (-3.96%)

, YDKN

Acquired by FNB

08:35
07/21/17
07/21
08:35
07/21/17
08:35
Recommendations
F.N.B., Acquired by FNB analyst commentary  »

F.N.B. weakness overdone,…

FNB

F.N.B.

$13.59

-0.56 (-3.96%)

YDKN

Acquired by FNB

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OFG

OFG Bancorp

$9.85

-0.1 (-1.01%)

08:34
07/21/17
07/21
08:34
07/21/17
08:34
Earnings
OFG Bancorp reports Q2 EPS 30c, consensus 27c »

OFG Bancorp reports Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

ENDP

Endo

$12.32

0.24 (1.99%)

08:32
07/21/17
07/21
08:32
07/21/17
08:32
Hot Stocks
Endo closing Huntsville manufacturing and distribution facilities »

Endo will be ceasing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

ADS

Alliance Data

$238.62

-24.91 (-9.45%)

08:30
07/21/17
07/21
08:30
07/21/17
08:30
Recommendations
Alliance Data analyst commentary  »

Alliance Data weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 05

    Sep

KCG

KCG Holdings

, TNGO

Tangoe

08:30
07/21/17
07/21
08:30
07/21/17
08:30
Options
Two option delistings on July 21st »

Option delistings…

KCG

KCG Holdings

TNGO

Tangoe

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGEN

Repligen

$42.17

0.13 (0.31%)

08:30
07/21/17
07/21
08:30
07/21/17
08:30
Initiation
Repligen initiated  »

Repligen initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.